Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,783 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1.
Schwarzer A, Oliveira M, Kleppa MJ, Slattery SD, Anantha A, Cooper A, Hannink M, Schambach A, Dörrie A, Kotlyarov A, Gaestel M, Hembrough T, Levine J, Luther M, Stocum M, Stiles L, Weinstock DM, Liesa M, Kostura MJ. Schwarzer A, et al. Among authors: levine j. Mol Cancer Ther. 2023 Nov 1;22(11):1290-1303. doi: 10.1158/1535-7163.MCT-22-0718. Mol Cancer Ther. 2023. PMID: 37643767 Free PMC article.
1-Thiazol-2-yl-N-3-methyl-1H-pyrozole-5-carboxylic acid derivatives as antitumor agents.
Cooper AB, Ciblat S, Shipps G, Levine J, Kostura M, Oza V, Constantineau-Forget L, Dery M, Grand-Maitre C, Bruneau-Latour N, Bellavance E, Patane M, Siddiqui A, Luther M. Cooper AB, et al. Among authors: levine j. Bioorg Med Chem Lett. 2017 Sep 15;27(18):4471-4477. doi: 10.1016/j.bmcl.2017.08.003. Epub 2017 Aug 2. Bioorg Med Chem Lett. 2017. PMID: 28844391
Corrigendum to "1-Thiazol-2-yl-N-3-methyl-1H-pyrozole-5-carboxylic acid derivatives as antitumor agents" [Bioorg. Med. Chem. Lett. 27 (2017) 4471-4477].
Cooper AB, Ciblat S, Shipps G, Levine J, Kostura M, Oza V, Constantineau-Forget L, Dery M, Grand-Maitre C, Bruneau-Latour N, Bellavance E, Patane M, Siddiqui A, Luther M. Cooper AB, et al. Among authors: levine j. Bioorg Med Chem Lett. 2018 Mar 1;28(5):985. doi: 10.1016/j.bmcl.2018.01.046. Epub 2018 Feb 9. Bioorg Med Chem Lett. 2018. PMID: 29433931 No abstract available.
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study.
Stein R, Turner D, Hussey S, Kawasmi A, Ledder O, Levine J, Markowitz J, Matar M, Orlanski-Meyer E, Russell RK, Shaoul R, Yerushalmy-Feler A, Mould DR, Conrad MA. Stein R, et al. Among authors: levine j. Aliment Pharmacol Ther. 2025 Jan 15. doi: 10.1111/apt.18484. Online ahead of print. Aliment Pharmacol Ther. 2025. PMID: 39812549
The Evolving Case for Skin Failure-Beyond Pressure Injury.
Berlowitz DR, Levine JM. Berlowitz DR, et al. Among authors: levine jm. JAMA Intern Med. 2025 Jan 13. doi: 10.1001/jamainternmed.2024.7461. Online ahead of print. JAMA Intern Med. 2025. PMID: 39804609
Impact of resection margin status on recurrence and survival in patients with resectable, borderline resectable, and locally advanced pancreatic cancer.
Rompen IF, Marchetti A, Levine J, Swett B, Galimberti V, Han J, Riachi ME, Habib JR, Imam R, Kaplan B, Sacks GD, Cao W, Wolfgang CL, Javed AA, Hewitt DB. Rompen IF, et al. Among authors: levine j. Surgery. 2025 Jan 10;180:109114. doi: 10.1016/j.surg.2024.109114. Online ahead of print. Surgery. 2025. PMID: 39798179
3,783 results